Physician profile
Nader Noorian
NPI 1861479057
$37,517.14
in general payments reported to CMS, 2019-2025
68 companies · $8,122 in 2025
The $8,122 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,502 · 2020: $2,402 · 2021: $4,643 · 2022: $4,661 · 2023: $3,708 · 2024: $7,479 · 2025: $8,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,050 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,179.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,050.00 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,857.37 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $3,296.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $3,015.19 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,679.98 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Amgen INC. | $1,755.84 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $1,716.33 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $1,584.26 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,584.21 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,397.32 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,380.30 | 2021-2025 | |
| Astellas Pharma US INC | $752.29 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $700.90 | 2023-2025 | Rexulti, Jynarque |
| Allergan, INC. | $560.83 | 2019-2020 | |
| Corcept Therapeutics | $546.86 | 2024-2025 | Korlym |
| Aimmune Therapeutics, INC. | $543.57 | 2024-2025 | Zenpep |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $534.75 | 2019-2022 | |
| Edwards Lifesciences Corporation | $530.89 | 2021-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Glaxosmithkline, LLC. | $465.37 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $438.31 | 2019-2023 | |
| Antares Pharma, INC. | $422.69 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Takeda Pharmaceuticals U.S.A., INC. | $391.93 | 2019-2021 | |
| Abbott Laboratories | $360.65 | 2019-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $307.81 | 2021-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $306.89 | 2019-2022 | |
| Shield Therapeutics INC | $279.43 | 2022-2024 | Accrufer |
| Exact Sciences Corporation | $274.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $267.70 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi-Aventis U.S. LLC | $240.74 | 2019-2025 | |
| Almatica Pharma LLC | $220.71 | 2023-2024 | Loreev Xr |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $200.56 | 2021-2022 | |
| Boston Scientific Corporation | $194.97 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $190.38 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $179.26 | 2022 | |
| Silk Road Medical, INC. | $167.28 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $161.52 | 2019-2020 | |
| Medtronic USA, INC. | $141.73 | 2019 | |
| Idorsia Pharmaceuticals US INC | $138.21 | 2023 | Quviviq |
| Genentech USA, INC. | $136.36 | 2020 | |
| Gilead Sciences, INC. | $115.29 | 2021-2025 | |
| Verity Pharmaceuticals INC. | $107.93 | 2024-2025 | Tlando |
| Ethicon INC. | $107.27 | 2022 | |
| Eisai INC. | $101.56 | 2020-2022 | |
| Inari Medical, INC. | $94.96 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Ibsa Pharma INC. | $92.99 | 2021-2025 | Tirosint, Flector, Licart |
| Teva Pharmaceuticals USA, INC. | $80.68 | 2019 | |
| Sanofi Pasteur INC. | $80.66 | 2019-2022 | |
| Lundbeck LLC | $75.53 | 2023-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $72.71 | 2021 | |
| Axsome Therapeutics, INC. | $70.24 | 2025 | Symbravo |
| Sumitomo Pharma America, INC. | $62.49 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.23 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $51.11 | 2021 | |
| Phathom Pharmaceuticals, INC. | $45.80 | 2024 | Voquezna |
| Arbor Pharmaceuticals, INC. | $45.11 | 2019-2020 | |
| Lucid Diagnostics INC. | $43.23 | 2022 | |
| Medtronic, INC. | $40.96 | 2025 | Kyphon Express II Kyphopak Tray |
| Horizon Therapeutics Plc | $38.58 | 2023 | Krystexxa |
| Acerus Pharmaceuticals Corporation | $28.46 | 2021 | |
| Sunovion Pharmaceuticals INC. | $26.71 | 2022 | |
| Clarus Therapeutics INC. | $23.96 | 2021 | |
| Bausch Health US, LLC | $19.85 | 2022 | |
| Dexcom, INC. | $18.71 | 2025 | Dexcom G6 Transmitter |
| Tolmar, INC. | $17.52 | 2025 | Jatenzo |
| Alfasigma USA, INC. | $16.12 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.74 | 2022 | |
| Biogen, INC. | $13.55 | 2021 | |
| Therapeuticsmd, INC. | $13.26 | 2019 | |
| Endogastric Solutions, INC | $9.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Noorian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.